Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vertex Pharmaceuticals (VRTX – Research Report) and Acutus Medical (AFIB – Research Report).
Vertex Pharmaceuticals (VRTX)
In a report released yesterday, Paul Matteis from Stifel Nicolaus maintained a Hold rating on Vertex Pharmaceuticals, with a price target of $263.00. The company’s shares closed last Thursday at $292.16, close to its 52-week high of $301.80.
According to TipRanks.com, Matteis is a 4-star analyst with an average return of
Vertex Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $292.88, which is a -0.8% downside from current levels. In a report issued on August 4, SVB Securities also maintained a Hold rating on the stock with a $265.00 price target.
See today’s best-performing stocks on TipRanks >>
Acutus Medical (AFIB)
BTIG analyst Marie Thibault reiterated a Buy rating on Acutus Medical yesterday and set a price target of $2.50. The company’s shares closed last Thursday at $1.66, close to its 52-week low of $0.48.
According to TipRanks.com, Thibault is a 4-star analyst with an average return of
Currently, the analyst consensus on Acutus Medical is a Moderate Buy with an average price target of $2.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VRTX:
- Stifel Nicolaus Remains a Hold on Light & Wonder (LNW)
- Stifel Nicolaus Sticks to Their Buy Rating for New Fortress Energy (NFE)
- Rivian Automotive (RIVN) Receives a Rating Update from a Top Analyst
- Stifel Nicolaus Sticks to Their Buy Rating for ESAB Corporation (ESAB)
- Analysts Offer Insights on Utilities Companies: W&T Offshore (WTI) and Western Midstream Partners (WES)
